Does Telisotuzumab belong to the targeted drug category?

Telisotuzumab (Telisotuzumab) is a targeted drug that belongs to the category of antibody drug conjugates (Antibody-Drug Conjugate, ADC). It is composed of monoclonal antibodies and cytotoxic drugs connected through stable chemical linkers. It can accurately identify and bind to specific targets on the surface of tumor cells, thereby delivering cytotoxic drugs directly to the interior of cancer cells to achieve the purpose of killing tumors. The design concept of terituzumab is to use the combination of targeting and drug release to improve the effectiveness and safety of treatment.

Territuzumab mainly targets the c-Met receptor (also known as stromal cell-derived factor receptor) on the surface of tumor cells. c-Met is abnormally expressed or overactivated in a variety of malignant tumors, promoting the growth, invasion and metastasis of tumor cells. By targeting c-Met, terituzumab can selectively attack tumor cells while reducing damage to normal cells, significantly improving the specificity and efficacy of treatment. c-Met Targeting strategy is currently one of the hot spots in cancer treatment research, and terituzumab has great potential in this field.

As a targeted therapy drug, terituzumab specifically recognizes and binds c-Met positive tumor cells, effectively delivers cytotoxic drugs into tumor cells, and induces tumor cell apoptosis and death. This precise drug delivery mechanism not only improves the tumor cell killing rate, but also reduces the systemic side effects caused by traditional chemotherapy drugs. Therefore, terituzumab is considered to be one of the important representatives in the current field of precision tumor treatment, especially suitable for patients with solid tumors such as c-Metpositive non-small cell lung cancer.

In general, terituzumab does fall into the category of targeted drugs, specifically antibody drug conjugates. It uses monoclonal antibodies targeting c-Met to accurately deliver cytotoxic drugs to tumor cells to achieve efficient tumor killing. With the deepening of clinical research and the continuous improvement of technology, terituzumab is expected to bring new treatment hope and better efficacy to more patients with c-Met-related tumors.

Reference materials:https://www.drugs.com/